Please login to the form below

Not currently logged in
Email:
Password:

Generic Zyprexa launched in US

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration (FDA).

It is the first generic olanzapine product to be marketed in the US. Lilly's Zyprexa is one of the biggest-selling drugs affected by the patent cliff, achieving global sales of $5.03bn in 2010.

Lilly has already seen the first affects of generic competition for Zyprexa in its financial results for the third quarter of 2011, with sales down 3 per cent for the period.

Teva's olanzapine tablets in 2.5mg, 5mg, 7.5mg, 10mg and 15mg doses and Dr Reddy's olanzapine tablets in 20mg doses have each been awarded a 180-day period of marketing exclusivity in the US, following an agreement made between the two companies in April 2011.

In addition, Dr Reddy's will launch its 2.5mg, 5mg, 7.5mg, 10mg ,15mg and 20mg of olanzapine tablets upon expiration of the 180-day exclusivity period.

Dr Keith Webber, deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research, said: "The approval of generic olanzapine offers greater access to a widely used treatment for mental illnesses. Having affordable treatment options is good for patients with long-term illnesses that must be carefully managed."

25th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics